Keros doses first patient in Phase 2 rinvatercept trial for Duchenne muscular dystrophy
Bitget2026/09/28 12:04- Keros Therapeutics dosed the first patient in a Phase 2 trial of rinvatercept for Duchenne muscular dystrophy.
- Initial results have not been presented; early data are expected in the first half of 2027.
- The study is intended to assess whether rinvatercept can improve outcomes for both ambulatory and non-ambulatory DMD patients.
- The milestone advances Keros’s neuromuscular pipeline, setting up a key clinical readout that could shape its development strategy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
